Background & Aims:
Introduction
Hepatitis C virus (HCV) infection is a common and an important comorbidity in HIVinfected patients 1,2 . Compared to HIV-monoinfected patients, HCV-coinfected patients have a higher risk for mortality 3, 4 . In the Canadian coinfection cohort, EuroSIDA, as well as the Swiss HIV Cohort Study (SHCS), hepatic decompensation and hepatocellular carcinoma were among the most common causes of death in recent years [5] [6] [7] . Achieving a sustained virological response (SVR) substantially reduces HCV related mortality and morbidity and prevents further HCV transmission 3, 6, 8 .
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This article is protected by copyright. All rights reserved. HCV genotype 1 infected patients 11, 12 . As these drugs still had to be combined to peg-IFN and RBV, only 13% of HCV genotype 1 infected patients started treatment after the approval of first generation PIs in Switzerland 13 . Thus these treatments only had a very modest impact on the burden of HCV disease at the population level. The new era of interferon-free second generation DAA improved safety and tolerability compared to previous interferon-based therapies. Accordingly, previously reported treatment barriers for peg-IFN/RBV therapy do not apply anymore in more than 60% of patients 9 . Cure rates above 90% are now achieved in all HCV genotypes and treatment efficacy is similar in HIV/HCV-coinfected patient compared to HCVmonoinfected ones 14 .
The World Health Organsization (WHO) defined ambitious targets with regard to viral hepatitis including a 65% reduction in mortality by 2030. To achieve this target, it is essential to understand the trends in HCV treatment uptake, and efficacy in real world settings. The SHCS provides an optimal framework to address the impact of DAAs in routine clinical practice in a nationwide representative HIV/HCV-coinfected population. The aims of this study were to assess the impact of new DAAs on treatment uptake and efficacy as well as its repercussion on liver disease burden in the SHCS.
Patients and methods

Study population:
The SHCS (www.shcs. 
Study periods:
We defined 3 distinctive analysis periods, based on the availability of HCV 
Assessment of HCV treatment:
Details on treatment safety, uptake and efficacy were assessed in all patients treated 
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DAA era) were retrieved from our previous studies as well as from the SHCS database 3, 13 .
To capture the key events during HCV treatment, a case-report form was According to previous studies in HIV/HCV-coinfected patients, we used the following cut-off values: 7.1kPa for Metavir F2, 9.5 kPa for Metavir F3, and 12.4 kPa for Metavir F4 (cirrhosis) 16 .
Statistical analysis:
Demographic and clinical characteristics at HCV treatment start were described using absolute numbers and proportions, or medians and interquartile ranges (IQR) for
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patients treated during period 3. Their main characteristics were compared to those of patients treated during period 2 using Chi-square, Fisher's exact or Mann-Whitney test, where appropriate. All testing was two-tailed and P-values < 0.05 were considered to indicate statistical significance. Treatment uptake was described as incidence of treatment initiations by period. Treatment uptake and efficacy, as well as liver fibrosis stages were compared between different time periods using the Chisquare test. Statistical analyses were performed using Stata Version 13.1.
Results
Characteristics of patients treated with 2 nd generation DAAs
At the beginning of the third period, 876 participants had a chronic HCV (Table 1) , of whom 55% received the fixed combination of SOF/ ledipasvir (LDV).
The combination of ombitasvir/ paritaprevir/ritonavir (OMV/PTV/RTV) and dasabuvir (DSV) was prescribed in 17/180 (9%). Additional ribavirin (RBV) was prescribed in one half of cases. Sixty-one percent (109/180) of the patients were treatmentexperienced, 97 with peg-IFN/RBV, 11 with a PI and 1 with SOF. In 88% of patients the indication to start treatment was liver fibrosis. From the 11 patients that started treatment because of extrahepatic manifestations, 3 had a vasculitis, 3 had a glomerulonephritis, 2 had a porphyria cutanea tarda, 2 had fatigue and 1 had a cryoglobulinemia.
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Changes in treatment uptake and efficacy over the three periods
Overall treatment uptake continuously increased through the 3 periods (from 4. 
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Changes in liver fibrosis stages over time
At the end of the second period in April 2014 data on liver fibrosis stages was available for 623 patients with a chronic HCV infection in the SHCS (Figure 2) . Of those, 33% (204/623) had advanced fibrosis (≥Metavir F3) of which158 (77%) had a cirrhosis. At the end of period 3, the proportion of patients with advanced fibrosis still to be treated declined to 15% (67/438) and only 12% (51/438) had a cirrhosis (p<0.01).
Discussion
After the approval of interferon-free second generation DAAs, we observed a 4-fold increase in treatment uptake and a 2-fold increase in treatment efficacy leading to
SVRs above 90% across all HCV genotypes in the SHCS. Even traditionally difficultto-treat, pre-treated patients with advanced liver fibrosis achieved high SVR rates with DAA treatments in a clinical routine setting. Because of treatment priorities and reimbursement limitations, three-quarters of patients treated with second generation DAAs had advanced fibrosis. The successful treatment of these patients led to a 2-fold reduction of patients with cirrhosis and a replicating HCV infection in the SHCS.
As in the French ANRS CO13-HEPAVIH cohort and the German hepatitis C cohort (GECCO), patients treated with second generation DAAs in the SHCS were predominantly middle aged, males, who previously injected drugs 17, 18 . In our study three-quarters of them had advanced fibrosis and 60% were previously treated, traditionally representing the difficult-to-treat population (Table 1 ). Similar findings were described in the French cohort, with 73% cirrhotic patients and 70% who had failed previous treatment. Ninety percent of patients were treated with a SOF based regimen and of those 55% received the fixed combination of SOF/LDV in the SHCS, which contrasts with the French cohort where a regimen containing SOF/DCV was predominantly used (68%). In the SHCS second generation DAA treatments were highly effective, leading to an overall SVR12 rate of 96%. Similar overall SVR12 rates were found in the French (92%) and the German (96%) cohorts. These data confirm that efficacy in real world settings is similar to those found in registered trials, with
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response rates in HIV/HCV-coinfected patients similar to those in HCVmoninfected [19] [20] [21] [22] . 24, 25 . The four virological failures in our study occurred among patients treated with only one DAA. Similarly, lowest cure rates were also described with the combination of SOF/RBV in the two other European cohorts, particularly among genotype 3 infected patients.
Compared to patients treated in the 1 st -generation DAA era, patients treated during the 2 nd -generation DAA era had significantly higher fibrosis stages and twice as much patients were cirrhotics (Table 2) . This reflects the improvements in treatment eligibility as contraindications to interferon-based therapy did not apply any more in the 2 nd -generation DAA era. But it is also driven by treatment prioritization of those with advanced liver disease and by reimbursement restrictions according to the Metavir stage.
We observed an increase in treatment uptake over time, especially in the last study period, when 2 nd generation DAA were available. Treatment uptake in the peg-IFN/RBV era was similarly low in the SHCS as in other European cohorts, ranging from 3.4 to 5.9 per 100 patient years 3, 26, 27 . Before 2011, less than one third of HIV/HCV-coinfected patients in the SHCS were eligible for treatment and only a minority started treatment 9, 10, 28 . Similar rates were found in a large registry of 99,166
US veterans with HCV viremia, were only 11.6% started treatment, and 57% of those not treated had contraindications to treatment 29 . After the approval of first generation DAAs (PIs, only against genotype 1) in Switzerland in September 2011, only 13% of HCV genotype 1 infected patients started treatment and treatment incidence increased only slightly in routine clinical care (from 3.8 to 6.1 per 100 patient-years), thereby only having a very modest impact on the burden of HCV disease at the population level 13 . In this period, we noticed a decrease in treatment uptake across
all other genotypes (Figure 1) , highlighting the fact that physicians postponed treatment awaiting for more efficient and more tolerable treatments for non-1 genotype infected individuals. In the 2 nd generation DAA era, we observed an impressive fourfold increase in treatment uptake, reaching a treatment incidence of 22 per 100 patient-years, which is close to the 25 per 100 patient-years found in with high risk behavior could be treated because they often had low fibrosis stages.
As the remaining patients to be treated often have mild fibrosis, the burden of replicating HCV infection will only be further reduced if reimbursement is not restricted to those with advanced fibrosis. Unfortunately, universal access to HCV therapy is restricted to few countries worldwide due to the huge costs of these treatments 33 . The successful negotiations with pharmaceutical companies in Australia and Egypt to substantially lower DAA costs exemplify that this can be achieved.
We report on one of the largest prospective observational studies assessing long- 
guidelines and reimbursement policies over time resulted in a heterogeneity of treatments used, precluding comparisons between different treatment regimens.
Rather than comparing the safety and efficacy of different regimens, our study focused on the description of the overall uptake, efficacy and tolerability of HCV therapy in routine clinical practice. As treatment uptake is directly linked to reimbursement policies, our data might not be generalizable to settings with different regulations.
In conclusion, we observed a substantial increase in treatment uptake and efficacy after the approval of interferon-free second generation DAA treatments. DAAs were well tolerated and highly efficacious, even among HIV/HCV-coinfected patients with advanced liver fibrosis or cirrhosis in the SHCS. The treatment of this population with advanced liver disease was driven by treatment priorities but also by limitations in reimbursement, and resulted in a significant reduction in the number of cirrhotic patients with replicating HCV. However many with mild fibrosis are still untreated.
Thus, we will only be able to further reduce the burden of replicating HCV infection if reimbursement is not restricted to those with advanced fibrosis. 
HIV characteristics
Median HIV RNA in log cp/ml (IQR) Controlled HIV RNA<20 copies/ml ( 
